Triglyceride deposit cardiomyovasculopathy
Conditions
Interventions
None listed
Sponsors
Hamamatsu University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Patient providing written informed consent
Exclusion criteria
Exclusion criteria: not applicable
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Composite endpoint including lethal arrhythmia, heart failure hospitalization, cardiovascular death, and all-cause mortality | — |
Secondary
| Measure | Time frame |
|---|---|
| Arrhythmic events including bradycardia, supraventricular tachycardia, and ventricular tachycardia Heart failure hospitalization Any hospitalization for the cardiovascular management, excluding heart failure Cardiovascular death All-cause mortality | — |
Countries
Japan
Contacts
Public ContactKenichiro Suwa
Hamamatsu University School of Medicine Internal Medicine III, Division of Cardiology
Outcome results
None listed